Nanobiotix S.A. (NBTX)
| Market Cap | 1.97B +375.8% |
| Revenue (ttm) | 38.27M |
| Net Income | -28.13M |
| EPS | -0.59 |
| Shares Out | 48.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,297 |
| Open | 39.01 |
| Previous Close | 40.00 |
| Day's Range | 38.43 - 40.99 |
| 52-Week Range | 8.03 - 57.14 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 45.35 (+16.88%) |
| Earnings Date | Sep 18, 2026 |
About NBTX
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Th... [Read more]
Analyst Summary
According to 5 analysts, the average rating for NBTX stock is "Strong Buy." The 12-month stock price target is $45.35, which is an increase of 16.88% from the latest price.
News
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Voting Rights and Shares Capital of the Company
PARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité d...
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance with...
Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029
(RTTNews) - Nanobiotix S.A. (NBTX), a clinical-stage biotechnology firm, reported a financial and operational update for its first quarter of 2026.
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
Nanobiotix Earnings release: Q1 2026
Nanobiotix released its Q1 2026 earnings on June 2, 2026, summarizing the period's financial results.
Nanobiotix Joins the Euronext Tech Leaders Index
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix Exercises Underwriters' Option In Global Offering, Gross Proceeds Reach $100 Mln
(RTTNews) - Nanobiotix S.A. (NBTX), a late-clinical stage company, on Friday announced that underwriters of its global offering had fully exercised the option to purchase additional American Depositar...
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix (NBTX) Sees a Significant Decline in Share Price
Nanobiotix (NBTX) Sees a Significant Decline in Share Price
Nanobiotix Announces Pricing Of Global Offering Worth $98 Mln
(RTTNews) - Nanobiotix S.A. (NBTX), a late-stage biotechnology company, on Thursday announced pricing of a follow-on global offering consisting of a public offering and an offering exclusively for qua...
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering ...
Nanobiotix Resumes Trading Of Ordinary Shares On Euronext Paris
(RTTNews) - Nanobiotix S.A. (NBTX), announced that, following a temporary halt earlier in that day, trading of its ordinary shares on Euronext Paris resumed at 3:30 p.m. Paris time (9:30 a.m. New York...
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix Temporarily Halts Paris Trading Amid Global Offering; Stock Slides
(RTTNews) - Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches for cancer and other major diseases, said trading of its ordinary shares...
Nanobiotix (NBTX) Plans â¬75M Global Offering to Support Development Initiatives
Nanobiotix (NBTX) Plans â¬75M Global Offering to Support Development Initiatives
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix (NBTX) Initiates â¬75 Million Global Follow-On Offering
Nanobiotix (NBTX) Initiates â¬75 Million Global Follow-On Offering
Nanobiotix announces EUR 75M global follow-on offering
Nanobiotix (NBTX) announces the launch, subject to market and other conditions, of an approximately EUR 75M global follow-on offering consisting of (i) a public offering of its American Depositary Sha...
Nanobiotix Announces Launch of Global Follow-On Offering
PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-...
Nanobiotix files EUR75M ordinary shares offering
16:23 EDT Nanobiotix (NBTX) files EUR75M ordinary shares offering
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch biotech stock is flying.
Nanobiotix price target raised to EUR 60 from EUR 34 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 60 from EUR 34 and keeps a Buy rating on the shares after the company presented updated efficacy…